This is a $599,234 firm fixed price contract awarded by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases (NIAID) to Celdara Medical, a small business biotechnology company, under the Small Business Innovation Research (SBIR) program. The contract is for research to discover parasite-derived tolerogenic adjuvants, which could potentially be used in new vaccine development. Celdara Medical conducts research and...
This is a Phase I Small Business Innovation Research (SBIR) contract awarded by the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases to Teichos Laboratories, LLC, a small business located in West Lafayette, IN. The $300,000 firm fixed price contract is for research on a novel TLR2 agonist-aluminum combination adjuvant to improve the quality and duration of the immune response. This SBIR contract was awarded under a solicitation that sought innovative...
This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases (HHS-NIH-NIAID) is valued at $600,000 to Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals, for work in Boston, MA from September 2020 through August 2022. The contract was awarded under the Small Business Innovation Research (SBIR) program's total small business set-aside solicitation seeking proposals on topics...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Tolka.ai Inc. (doing business as Tolka AI Therapeutics), a for-profit small business. The contract, valued at $299,993.00, is for research and development efforts related to NIAID's mission needs and SBIR program objectives. The original solicitation included a variety of research topics,...
Teichos Laboratories, LLC, a small business, has been awarded a $300,000 firm fixed-price definitive contract by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases. The contract is to support research and development efforts on "Augmenting the Quality and Duration of the Immune Response with a Novel TLR2 Agonist-Aluminum Combination Adjuvant." This contract is set aside for total small business participation....
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $300,000 definitive contract to Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals, as part of the Small Business Innovation Research Program Phase I Action. The contract is a firm fixed price award with a period of performance from July 5, 2022 through November 30, 2023 to be performed in Canton, Massachusetts. The award is set aside for...
The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded a $4,148,210.00 Firm Fixed Price Definitive Contract to Metaclipse Therapeutics Corp, a self-certified small disadvantaged business, for the development of membrane-anchored cytokines as novel vaccine adjuvants for the elderly. This contract, which has a completion date of December 31, 2022, is part of the agency's "DEVELOPMENT OF MEMBRANE ANCHORED...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a firm-fixed-price definitive contract valued at $585,999.00 to Protein Innovation Labs, Inc., a small business concern, for the provision of reagents to support immunologic analysis of non-mammalian models. This contract was awarded under the National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC) Small Business Innovation...
This $599,526 Firm Fixed Price contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Enepret Incorporated, a for-profit manufacturer located in Lexington, Kentucky. The contract is for "Adjuvant Discovery and Down-Selection for Vaccines against Infectious and Immune-Mediated Diseases" and supports NIAID's broader program goals related to "A More Durable and Universal Adjuvanted...
This firm-fixed-price SBIR Phase I contract was awarded by the Department of Health and Human Services' National Institute of Allergy and Infectious Diseases to HDT Bio Corp, a for-profit biopharmaceutical company. The $599,629 contract funds the "Rational Development of a Combination Nanoparticle Adjuvant for Influenza", which involves research and development of novel adjuvants and other medical countermeasures. HDT Bio Corp has previously served as a prime contractor on other HHS...